JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Phase 2

Completed

• Conditions: Recurrent Classical Hodgkin Lymphoma
• Interventions: Drug: Ruxolitinib

• Registration Number: NCT02164500
• Lead Sponsor: University of Cologne

Brief Summary

The Purpose of this trial is:

* to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL

* to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-06-12
• Study First Submitted QC: 2014-06-12
• Study First Posted: 2014-06-16
• Study Start: 2015-10
• Primary Completion: 2019-05-17
• Study Completion: 2019-05-17
• Status Verified: 2020-04
• Last Update Submitted: 2020-04-03
• Last Update Posted: 2020-04-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• relapsed or refractory HL
• ECOG <= 2,
• no major organ dysfunction
• written informed consent

Exclusion Criteria

• history of another primary malignancy ≤ 2 years
• female patients who are pregnant or breast feeding
• patients with a known history of HIV seropositivity
• chronic active hepatitis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ruxolitinib	Ruxolitinib	-

Primary Outcome Measures

Name	Time	Method
overall response rate	8 weeks

Trial Locations

Locations (1)

1st Dept. of Medicine, Cologne University Hospital; 🇩🇪 Cologne, Germany